Exelixis, Inc. (NASDAQ:EXEL) Director Stelios Papadopoulos sold 10,000 shares of the stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $25.40, for a total value of $254,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Stelios Papadopoulos also recently made the following trade(s):
- On Monday, September 18th, Stelios Papadopoulos sold 72,210 shares of Exelixis stock. The stock was sold at an average price of $27.76, for a total value of $2,004,549.60.
- On Tuesday, September 19th, Stelios Papadopoulos sold 200,000 shares of Exelixis stock. The stock was sold at an average price of $27.68, for a total value of $5,536,000.00.
Exelixis, Inc. (NASDAQ EXEL) traded down 12.64% on Friday, hitting $24.47. The stock had a trading volume of 10,841,219 shares. The company has a 50-day moving average price of $27.08 and a 200-day moving average price of $23.49. Exelixis, Inc. has a 52 week low of $10.04 and a 52 week high of $29.50. The stock has a market capitalization of $7.19 billion, a price-to-earnings ratio of 123.59 and a beta of 1.97.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The company’s quarterly revenue was up 173.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.15) EPS. Equities research analysts anticipate that Exelixis, Inc. will post $0.27 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/09/23/exelixis-inc-exel-director-stelios-papadopoulos-sells-10000-shares-of-stock.html.
Several large investors have recently bought and sold shares of EXEL. BlackRock Inc. raised its holdings in shares of Exelixis by 33,678.5% in the 1st quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock worth $415,099,000 after purchasing an additional 19,098,757 shares during the period. Vanguard Group Inc. raised its holdings in Exelixis by 12.8% during the 1st quarter. Vanguard Group Inc. now owns 23,735,071 shares of the biotechnology company’s stock valued at $514,339,000 after acquiring an additional 2,696,877 shares during the period. Matrix Capital Management Company LP raised its holdings in Exelixis by 8.8% during the 2nd quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock valued at $372,343,000 after acquiring an additional 1,225,000 shares during the period. Janus Henderson Group PLC bought a new stake in Exelixis during the 2nd quarter valued at $28,689,000. Finally, Meditor Group Ltd raised its holdings in Exelixis by 5.5% during the 2nd quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock valued at $498,258,000 after acquiring an additional 1,046,000 shares during the period. 79.20% of the stock is currently owned by institutional investors.
Several equities research analysts recently issued reports on EXEL shares. William Blair reissued an “outperform” rating on shares of Exelixis in a research note on Friday, June 16th. Oppenheimer Holdings, Inc. began coverage on Exelixis in a research note on Monday, June 12th. They issued a “hold” rating on the stock. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $29.00 price objective on the stock in a research note on Tuesday, July 11th. Cann reissued a “hold” rating on shares of Exelixis in a research note on Thursday, July 20th. Finally, BidaskClub raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Friday, August 25th. Six analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $26.51.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.